肿瘤标志物在乳腺癌诊断及预后中的应用  

Application of tumor markers in breast cancer diagnosis and prognosis

作　　者：董晓民[1] 钟理[1,2] 樊江平[1] 陈保平[3] 臧爱民[3] 

机构地区：[1]河北大学生命科学学院生物芯片研究室,河北保定071002 [2]Western University of Health Sciences [3]河北大学附属医院肿瘤外科,河北保定071002

出　　处：《基础医学与临床》2012年第8期960-963,共4页Basic and Clinical Medicine

基　　金：国家自然科学基金(81071795)

摘　　要：肿瘤标志物已广泛应用于乳腺癌的诊断及预后。本综述总结了肿瘤抗原15-3(CA15-3)、人表皮生长因子受体2(HER2)、雌激素受体(ER)及黄体酮受体(PR)等经典乳腺癌标志物的临床应用现状及新兴乳腺癌生物标志的临床价值。多标志物的联合检测较单一标志物有更高的灵敏度及特异性,将成为今后乳腺癌标志物的临床应用趋势。Tumor markers have been widely used in diagnosis and prognosis of breast cancer. This article reviews the clinical application of classic breast cancer biomarkers, such as CA15-3, HER2, ER and PR, and the potential values of emerging biomarkers of breast cancer. Combined detection with multi-biomarkers has higher sensitivity and specificity than detection with single tumor marker, and this finding may orient the application of breast cancer biomarkers in clinical treatment.

关 键 词：肿瘤标志物 乳腺癌 诊断 预后 

分 类 号：R737.9[医药卫生—肿瘤]